VivoSeq
Other

PD-L1 Positive

0

Pipeline Programs↗

5

Active Trials↗

2

Companies Involved↗

PD-L1 Positive is an early-stage landscape with 0 programs across 2 companies. The most active players are Regeneron, Effector Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

0/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Regeneron logo

Regeneron

0 programs

PreclinicalE

Effector Therapeutics

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

8

clinical trials

Active, not recruiting3 · 38%
Recruiting1 · 13%
Terminated1 · 13%
Not yet recruiting1 · 13%
Unknown status1 · 13%
Withdrawn1 · 13%

Clinical Trials

Trial Activity

8 trials

Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC
Recruiting·UUniversität des Saarlandes·Phase 3·NCT07026474·214 enrolled
A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients
Active, not recruiting·SShanghai Chest Hospital·Phase 2·NCT05078931·35 enrolled
Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma
Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT05980000·37 enrolled
Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)
Active, not recruiting·EEffector Therapeutics·Phase 2·NCT04622007·68 enrolled
A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC
Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT07040644·150 enrolled
Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Adult Participants With Advanced PD-L1 Positive Malignancies
Terminated·Regeneron logoRegeneron·Phase 1·NCT03746704·2 enrolled
Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC
Withdrawn·UUniversity of Colorado, Denver·Phase 2·NCT05233696
89Zr-labeled KN035 PET Imaging in Patients With PD-L1 Positive Solid Tumors
Unknown status·WWuxi No. 4 People's Hospital·N/A·NCT04977128·20 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)